Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia

[Jm954]

Journal of Hematology & Oncology, November 2018

CAR-T therapy, a promising adoptive T cell immunotherapy, has become more and more important in the treatment of CLL. In the last 2 years, enormous progress has been witnessed in CAR-T therapy for CLL. However, no comprehensive review had been reported so far. This review summarizes the development of CAR-T therapy in CLL.

T cell senescence and CAR-T cell exhaustion receive more and more attention . To some extent, these problems limit the application of CAR-T therapy in CLL. In the future, combination with new drugs such as ibrutinib, venetoclax, and idelalisib, and sequential infusion of CAR-T cells targeting multiple antigens like CD19, CD23, and FcμR may be the trend of CAR-T therapy for CLL.

The extensive review is here: jhoonline.biomedcentral.com...

Quite long but worth a read.

Jackie

[NooNoo14]

Thanks for posting that Jackie. That actually clarified a few things for me ref this new treatment. Did you watch the programme last night - A Year to Save My Life - Dr George McGavin (BBC4). Not related to CLL but ref CAR-T?

Netty

[Jm954 Administrator in reply to NooNoo14]

No, I’ll have a look on catch up. Thank you!